Firibastat: A Novel Brain Aminopeptidase Inhibitor - A New Era of Antihypertensive therapy.
Curr Probl Cardiol
; 47(9): 100859, 2022 Sep.
Article
em En
| MEDLINE
| ID: mdl-33994025
ABSTRACT
Global incidence and prevalence of hypertension continues to increase and remains a significant challenge. The ever-increasing number of cases are due to comorbid conditions such as obesity and diabetes, as well as lifestyle indiscretions such as excessive salt intake. Hypertension, congestive heart failure, and kidney disease are all conditions resulting from abnormal Renin-Angiotensin-Aldosterone activation and adverse remodeling. Firibastat, a novel Brain Aminopeptidase inhibitor, may be able to help achieve blood pressure control in those with resistant hypertension. In this review article, we will discuss the biochemical pathway of firibastat and various trials assessing drug efficacy in animals and humans. This drug has the potential to curb the risk of uncontrolled hypertension and help improve long term cardiovascular morbidity and mortality.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Ácidos Sulfônicos
/
Dissulfetos
/
Hipertensão
/
Anti-Hipertensivos
Tipo de estudo:
Risk_factors_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Curr Probl Cardiol
Ano de publicação:
2022
Tipo de documento:
Article